ASSESSMENT OF PATTERN OF ADVERSE DRUG REACTIONS FROM ANTI-CANCER DRUGS IN A TERTIARY CARE HOSPITAL: A CROSS-SECTIONAL STUDY
##plugins.themes.academic_pro.article.main##
Abstract
BACKGROUND: Chemotherapy is one of the multimodal approaches to the treatment of cancer and adverse drug reactions (ADRs) are very commonly related with these anti-cancer agents. The present study is done with the aim to assess the pattern of adverse drug reactions due to anti-cancer therapy, analyse their causality and severity, and assess the pattern of drugs used for the treatment of adverse drug reactions.
MATERIALS AND METHODS: A cross-sectional study was conducted at a tertiary care teaching hospital for one year after obtaining approval from the ethics committee. All the cancer patients of either sex with age >18 years, admitted in the oncology department were included in the study. A pre-designed proforma was used for filling demographic, clinical, and prescribing details of the patient. Causality and severity of adverse drug reactions were assessed by using the WHO-UMC causality scale and Modified Hartwig and Seigel severity scale, respectively.
RESULTS: Out of 126 cancer patients enrolled in the study, 65% were females while 35% were males. The majority (30%) of the total study participants were in the age group of 51-60 years. A total of 259 ADRs were observed in cancer patients. 83% of the total ADRs were probable/likely in causality and 74% were mild ADRs. It was observed that fatigue, weakness, and dizziness were the most commonly occurring ADRs for which multivitamins were prescribed. The most common class of drug implicated in causing ADRs was Platinum coordination complex.
CONCLUSION: ADR monitoring is needed with anti-cancer drug management, to increase patient compliance and decrease hospital stay. Management of ADRs beforehand will help in reducing the suffering of patients and increase compliance. ADR monitoring is the need of the hour especially in cancer patients in order to increase patient compliance and decrease morbidity.
KEYWORDS: ADRs, Anti-cancer agents, Pharmacovigilance, Management of ADRs, Causality, Severity.
##plugins.themes.academic_pro.article.details##
References
-
1. Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. International journal of cancer, 149(4), 778-789.
2. World Health Organization. (2016). The use of the WHO-UMC system for standardised case causality assessment 2011.
3. Chakraborty, D., Kale, R. S., Das, L., Das, M., & Kirde, S. (2021). Pharmacovigilance Study of Anticancer Drugs in a Tertiary Care Rural Hospital in Central India. Biomedical and Pharmacology Journal, 14(2), 597-606.
4. Krishnarajan, D., Sivasakthi, K., Ariyamol, R., Kumar, D. N., & Varghese, S. (2021). A prospective observational study of chemotherapy-induced adverse drug reaction and the quality of life in cancer patients in a tertiary care hospital. Journal of Cancer Research and Therapeutics, 17(2), 530.
5. Koliyakodu, P. S., Sudhakar, R., Kurian, M. M., Jishnu, R. K., Kumar, R., Lalitha, V., ... & Sivakumar, T. (2021). A Prospective Observational Study on Evaluation of Chemotherapy Induced Adverse Drug Reactions in Cancer Patients in a Tertiary Care Hospital. Indian Journal of Pharmacy Practice, 14(1).
6. Behera, S. K., Kishtapati, C. R., Gunaseelan, V., Dubashi, B., Chandrasekaran, A., & Selvarajan, S. (2017). Chemotherapy induced adverse drug reactions in cancer patients in a tertiary care hospital in South India. Journal of Young Pharmacists, 9(4), 593.
7. WHO-UMC standardized case causality assessment. 2011. Available at: http://who umc.org/Graphics/24734.pdf.
8. Hartwig, S. C., Siegel, J., & Schneider, P. J. (1992). Preventability and severity assessment in reporting adverse drug reactions. American journal of hospital pharmacy, 49(9), 2229-2232.
9. Soldin, O. P., Chung, S. H., & Mattison, D. R. (2011). Sex differences in drug disposition. Journal of Biomedicine and Biotechnology, 2011.
10. Koliyakodu, P. S., Sudhakar, R., Kurian, M. M., Jishnu, R. K., Kumar, R., Lalitha, V., ... & Sivakumar, T. (2021). A Prospective Observational Study on Evaluation of Chemotherapy Induced Adverse Drug Reactions in Cancer Patients in a Tertiary Care Hospital. Indian Journal of Pharmacy Practice, 14(1).
11. Ramasubbu, S. K., Pasricha, R. K., Nath, U. K., & Das, B. (2020). Frequency, nature, severity and preventability of adverse drug reactions arising from cancer chemotherapy in a teaching hospital. Journal of Family Medicine and Primary Care, 9(7), 3349.
12. Wahlang, J. B., Laishram, P. D., Brahma, D. K., Sarkar, C., Lahon, J., & Nongkynrih, B. S. (2017). Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Therapeutic advances in drug safety, 8(2), 61-66.
13. Rout, A., Panda, R. K., Mishra, V., Parida, P., & Mohanty, S. (2017). Pharmacovigilance in cancer chemotherapy in regional cancer center of Eastern India: prospective observational study. Int J Basic Clin Pharmacol, 6(8), 1910.
14. Prasad, A., Datta, P. P., Bhattacharya, J., Pattanayak, C., Chauhan, A. S., & Panda, P. (2013). Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Eastern India. J Pharmacovigilance, 1(2), 107.
15. Chopra, D., Rehan, H., Sharma, V., & Mishra, R. (2016). Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey. Indian Journal of Medical and Paediatric Oncology, 37(01), 42-46.
16. Guduru, H., Jeevanagi, S. K. R., Nigudgi, S., & Bhandare, S. V. (2019). A prospective study on the prescription pattern of anti-cancer drugs and adverse drug reaction in a tertiary care hospital.
17. Aghamohammadi, H., Shrestha, S., Kavousi, S., & Milton, B. (2019). Assessment of prescribing pattern of chemotherapy drugs and monitoring of adverse drug reaction in cancer patients. Int J Pharm Sci Invent, 8, 42-51.
18. Amartya, D. E. (2010). Monitoring of suspected adverse drug reactions in oncology unit of an urban multispeciality teaching hospital. International Journal of Research in Pharmaceutical and Biomedical Sciences, 1(2), 1-32.